Article

Selank: the tuftsin analogue and its research record

Published 21 October 2026 · CognitivePepti Research Desk

Abstract chain of seven linked spheres in muted blue and grey tones against a pale background, suggesting a short peptide sequence

Prepared by: Research Desk. Sources are linked for verification.

Published 21 October 2026

At a glance

Type: synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Origin: developed at the Institute of Molecular Genetics in Moscow as an analogue of tuftsin, an endogenous immunomodulatory peptide
Research stage: the record summarised here consists of rat and cell-culture studies, which do not establish clinical efficacy
Regulatory status: not an FDA-approved drug. FDA's page on bulk drug substances that may present significant safety risks lists "Selank acetate (TP-7)", citing a possible immunogenicity risk from aggregation and peptide-related impurities and a lack of safety information. Selank is not named on the July 2026 Pharmacy Compounding Advisory Committee agenda.

What Selank is

Selank is a short synthetic peptide. Its sequence begins with Thr-Lys-Pro-Arg and ends with a Pro-Gly-Pro tripeptide. The Moscow group that developed it described it as an analogue of tuftsin, a naturally occurring peptide associated with immune regulation.

The Pro-Gly-Pro ending places Selank among the proline-rich peptides known as glyprolines. In a 2005 review in Pathophysiology, Ashmarin et al. argued that peptides carrying this motif are considerably more stable in biological media than most regulatory peptides. They grouped Selank with Semax as "hybrid" peptides, in which a natural regulatory fragment is joined to a stabilising glyproline tail.

Research history

Selank came out of the same Moscow programme on regulatory peptides that produced Semax. The indexed Selank papers summarised on this page date from 2008 onwards and address two broad questions: whether Selank alters neurotrophic factor expression in the rodent brain, and whether it is associated with shifts in expression of genes linked to neurotransmission, particularly GABAergic signalling. Alongside the rat tissue studies, at least one study has examined GABAergic gene expression in a human-derived cell line.

For wider context, see the cognition peptide research guide.

Mechanisms studied in preclinical work

The studies below were carried out in rats or cultured cells. They describe changes in molecular markers, not outcomes in people.

Neurotrophin expression. Inozemtseva et al. (2008) reported that intranasal Selank regulated expression of brain-derived neurotrophic factor (BDNF) in the rat hippocampus. BDNF is a protein involved in the growth and survival of nerve cells.
Neurotransmission-related genes. Volkova et al. (2016) examined Selank-associated expression changes in neurotransmission-related genes in the rat frontal cortex, including genes associated with GABAergic signalling.
Cell-line work. Filatova et al. (2017) tested GABAergic gene expression in IMR-32 cells. The authors reported that Selank alone did not change mRNA levels of the measured genes, while effects differed under combination conditions.

These papers point to research interest in BDNF and GABA-related pathways. They do not identify a receptor or a confirmed molecular mechanism. Because the rat and cell studies used different models and did not necessarily measure the same genes or endpoints, their results cannot be directly compared from the information summarised here.

The published research landscape

Concentration of origin. Selank was designed by a Moscow group, and the review that frames its design rationale comes from the same research school. The authorship and affiliations of the later papers are not detailed here, so the extent of independent replication cannot be judged from this summary.

Reliance on expression read-outs. Much of the work measures mRNA or protein levels. These are indirect proxies and do not on their own show functional effects on behaviour or physiology.

No controlled human data in the record summarised. The sources used for this page contain no randomised, placebo-controlled human trials of Selank, so no statements about effects in people can be drawn from them.

Regulatory status

United States, compounding framework. FDA maintains a list of bulk drug substances that may be used in compounding under section 503A. FDA materials distinguish listed from unlisted substances, and inclusion is not FDA approval of a drug (FDA document; FDA document). Selank is not an FDA-approved drug, and its appearance on FDA's safety-risk page (below) does not indicate approval or permission for compounding.
Safety-risk listing. FDA's page on bulk drug substances that may present significant safety risks lists "Selank acetate (TP-7)". FDA states that it may pose a risk of immunogenicity due to aggregation and peptide-related impurities, and that the agency lacks safety information. The same page also lists emideltide (DSIP).
Advisory committee, July 2026. The agenda for the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting lists peptides under consideration for the 503A list, including emideltide (DSIP), Semax and Epitalon. Selank is not named. For DSIP, see the DSIP research overview.

Open research questions

Receptor and target. No receptor is identified in these studies, and how a tuftsin-derived sequence relates to the reported expression changes is unresolved.
Consistency across models. The rat tissue studies and the IMR-32 cell study used different systems and conditions. Studies designed to measure the same genes under matched conditions would be needed to establish whether findings carry across models.
Role of the glyproline tail. The stabilising function of Pro-Gly-Pro is a design rationale; its contribution relative to the tuftsin-derived portion is untested in the work summarised.
Functional relevance. Whether the reported expression changes correspond to measurable functional outcomes in animal models is not addressed by the studies listed here.
Independent replication. Core findings would be strengthened by laboratories outside the originating research programme.

Limitations of the evidence

Mechanistic data come from rats and a single cell line.
Most studies measure gene or protein expression rather than functional outcomes.
Selank's design and framing come from a single Moscow research school, and independent replication is not evident in this summary.
Some Selank papers lacked verifiable links in the source material and were left out.
On the regulatory side, FDA records list Selank acetate (TP-7) among bulk drug substances that may present significant safety risks, citing immunogenicity concerns and a lack of safety information; no FDA approval is recorded.

Where researchers source it

Purita is a store that lists Selank for laboratory research use only. Its product page labels the item for research use only and not for human or animal administration.

Purita product page

Affiliate disclosure: this is a paid link. CognitivePepti earns a commission if a purchase is made through it, at no extra cost to the buyer. A listing is not an endorsement or a statement about product quality. See the affiliate disclosure.